Agree Luna, bad decision for them. We have a drug for an unmet medical need that had p3 trial results better than expected. There’s no way FDA will drag its foot in approving this one. We have another one coming that is best in class(VOS) and another unmet medical need that is a shoo in already for its efficacy and especially safety (FGMS). No way this is not noticed by the BP. Luna, do you have anything about potential indications? ILJIN hopes and prays it’s not bought out in two months.
News 
Market Data 
Discover 
